Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
105 hedge funds and large institutions have $197M invested in Antares Pharma, Inc. in 2018 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 33 increasing their positions, 29 reducing their positions, and 12 closing their positions.
33% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 12
26% more capital invested
Capital invested by funds: $157M → $197M (+$40.2M)
14% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 29
4% more funds holding
Funds holding: 101 → 105 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
25% less call options, than puts
Call options by funds: $465K | Put options by funds: $617K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$3.77M |
| 2 |
Millennium Management
New York
|
+$2.13M |
| 3 |
JP Morgan Chase
New York
|
+$1.54M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.53M |
| 5 |
Two Sigma Investments
New York
|
+$811K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$9.05M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$5.9M |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$4.01M |
| 4 |
MWP
MYCIO Wealth Partners
Philadelphia,
Pennsylvania
|
-$849K |
| 5 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$229K |
ATRS Hedge Fund Activity: Q3 2018 in Review
105 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q3 2018, worth a combined $197M — up 26% from $157M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ATRS positions and 12 closed out — a net gain of 4 holders — while 33 added to existing stakes and 29 trimmed.
The largest buyer was State Street, adding an estimated $3.77M. The largest seller was Armistice Capital, cutting an estimated $9.05M.
- 105 institutional investors held Antares Pharma, Inc. (ATRS) as of Q3 2018, up from 101 in Q2 2018.
- Funds reported $197M of Antares Pharma, Inc. stock for Q3 2018, up 26% quarter-over-quarter.
- 16 funds opened new Antares Pharma, Inc. positions in Q3 2018 and 12 closed out, a net change of +4 holders.
- The largest Antares Pharma, Inc. buyer in Q3 2018 was State Street, an estimated $3.77M added.
- The largest Antares Pharma, Inc. seller in Q3 2018 was Armistice Capital, an estimated $9.05M sold.
Based on aggregated 13F filings for Q3 2018.